April 7, 2022
--
Validity Diagnostics (“VDX”), a developer and manufacturer of diagnostic products used in drug screening, announced that the United States Patent and Trademark Office (“USPTO”) has granted two of its pending patent applications.
The first patent, U.S. Patent No. 11,214,821, relates to “reagents and methods of use with automated analyzers for obtaining a specific gravity index for urine”. This patent relates to the use of reagents in automated laboratory equipment to determine whether the specific gravity of a urine sample is abnormal, which is an indication of adulteration.
The second patent, U.S. Patent No. 10,571,457, relates to “methods for the detection of oxidative adulterants in urine sample”. This patent relates to methods of confirming the presence of an adulterant in a urine sample by using a reagent capable of reacting with uric acid and non-urate markers.
VDX was founded in 2015 and primarily sells its diagnostic products to medical laboratories. Since its beginnings, the company has created and applied for five patents to detect substance use disorder.
Authors: Matt Erdman and Larissa Fulop